Synergistic active targeting of dually integrin α v β 3 /CD44-targeted nanoparticles to B16F10 tumors located at different sites of mouse bodies

Shi, Sanjun; Zhou, Min; Li, Xin; Hu, Min; Li, Chenwen; Li, Min; Sheng, Fangfang; Li, Zhuo-heng; Wu, Guolin; Luo, Minghe; Cui, Huanhuan; Li, Ziwei; Fu, Ruoqiu; Xiang, Ming; Xu, Jing; Zhang, Qian; Lü, Lei

doi:10.1016/j.jconrel.2016.05.050

Cited by 71 publications

(48 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Integrin αvβ3 and its T4 receptor have also been implicated in the process of cancer metastasis [ 16 , 17 , 18 ]. Tetrac in its small molecule formulation acts as a T4 antagonist at the αvβ3 integrin [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

Contributions of Thyroid Hormone to Cancer Metastasis

et al. 2018

View full text Add to dashboard Cite

Acting at a cell surface receptor on the extracellular domain of integrin αvβ3, thyroid hormone analogues regulate downstream the expression of a large panel of genes relevant to cancer cell proliferation, to cancer cell survival pathways, and to tumor-linked angiogenesis. Because αvβ3 is involved in the cancer cell metastatic process, we examine here the possibility that thyroid hormone as l-thyroxine (T4) and the thyroid hormone antagonist, tetraiodothyroacetic acid (tetrac), may respectively promote and inhibit metastasis. Actions of T4 and tetrac that are relevant to cancer metastasis include the multitude of synergistic effects on molecular levels such as expression of matrix metalloproteinase genes, angiogenesis support genes, receptor tyrosine kinase (EGFR/ERBB2) genes, specific microRNAs, the epithelial–mesenchymal transition (EMT) process; and on the cellular level are exemplified by effects on macrophages. We conclude that the thyroid hormone-αvβ3 interaction is mechanistically linked to cancer metastasis and that modified tetrac molecules have antimetastatic activity with feasible therapeutic potential.

show abstract

Section: Introductionmentioning

confidence: 99%

Contributions of Thyroid Hormone to Cancer Metastasis

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Target delivery of pharmacotherapeutic compounds to the disorder sites is more effective. It is urgently required, but also challenging . Their surfaces were modified with ligands, targeting molecules, or peptides, which could deliver higher levels of drugs to the nidus sites and create an improved therapeutic effect.…”

Section: Targeted Drug Delivery Strategies For the Treatment Of Metabmentioning

confidence: 99%

Drug Delivery Strategies for the Treatment of Metabolic Diseases

Shi

Kong

Feng

et al. 2019

Adv Healthcare Materials

Self Cite

View full text Add to dashboard Cite

Metabolic diseases occur when normal metabolic processes are disrupted in the human body, which can be congenital or acquired. The incidence of metabolic diseases worldwide has reached epidemic proportions. So far, various methods including systemic drug therapy and surgery are exploited to prevent and treat metabolic diseases. However, current pharmacotherapeutic options for treatment of these metabolic disorders remain limited and ineffective, especially reducing patient compliance to treatment. Therefore, it is desirable to exploit effective drug delivery approaches to effectively treat metabolic diseases and reduce side effects. This brief review summarizes novel delivery strategies including local, targeted, and oral drug delivery strategies, as well as intelligent stimulus‐responsive drug delivery strategy, for the treatment of metabolic disorders including diabetes, obesity, and atherosclerosis.

show abstract

“…For example, CD44 and integrin a v b 3 have been the targets of two nanoparticle platforms: a core-shell system for gene delivery in melanoma models (27) and solid lipid nanoparticles for delivery of docetaxel (28). Self-assembled hydrogel nanoparticles were dually targeted to integrin a v b 3 and FR, loaded with paclitaxel, and validated in preclinical hepatocellular carcinoma models by Shu et al (Fig.…”

Section: Dual-targeted Nanoparticlesmentioning

confidence: 99%

Dual-Targeted Molecular Imaging of Cancer

et al. 2018

View full text Add to dashboard Cite

Molecular imaging is critical to personalized and precision medicine. Although singly targeted imaging probes are making an impact both clinically and preclinically, molecular imaging strategies using bispecific probes have enabled improved visualization of cancer in recent years through synergistic targeting of two ligands. In this Focus on Molecular Imaging review, we outline how peptide-, antibody-, and nanoparticle-based platforms have affected this emerging strategy, providing examples and pointing out areas in which the greatest clinical impact may be realized.

show abstract

Synergistic active targeting of dually integrin α v β 3 /CD44-targeted nanoparticles to B16F10 tumors located at different sites of mouse bodies

Cited by 71 publications

References 48 publications

Contributions of Thyroid Hormone to Cancer Metastasis

Contributions of Thyroid Hormone to Cancer Metastasis

Drug Delivery Strategies for the Treatment of Metabolic Diseases

Dual-Targeted Molecular Imaging of Cancer

Contact Info

Product

Resources

About